"Tumor lysate electroloaded mature human DC exhibit enhanced antigen-specific potency compared to lysate co-incubation in clinical manufacturing scale"
GAITHERSBURG, Md. and YOKOHAMA, Japan, Oct. 2 /PRNewswire/ -- MaxCyte, Inc. and Medinet Co., Ltd. (TSE: #2370) announce a joint poster presentation at The 10th International Symposium on Dendritic Cells. The meeting is being held October 1-5, 2008 in Kobe, Japan.
The presentation is entitled: "Tumor lysate electroloaded mature human DC exhibit enhanced antigen-specific potency compared to lysate co-incubation in clinical manufacturing scale" and will discuss the findings of a study that combined MaxCyte's platform and Medinet's novel immunocell therapy technologies to produce more potent cancer vaccines. The session is scheduled for Friday October 3rd from 1-2 pm and 6:15-8:00 pm.
The study was performed under an exclusive license, development and supply agreement to use MaxCyte's proprietary cell loading system to support clinical development and commercialization of Medinet's cancer immunotherapy service in Japan. MaxCyte has optimized its technology platform for Medinet's novel cancer immuno-cell therapy service for implementation in a closed system, cGMP manufacturing process at Medinet's cell processing centers.
The presentation will discuss how the electroloading of previously matured DC with whole cell tumor lysates generates a DC vaccine that has up to 20-fold enhanced antigen-specific potency compared to traditional DC vaccines obtained via lysate co-incubation of immature DC, followed by maturation. Direct loading of mature DC also saves significant processing time. Using
MaxCyte's cell-loading technology, this process was successfully scaled
up to allow processing of large, clinically relevant volumes of DC (>100
million cells) in a closed system, as a single lot that can be subsequently
cryopreserved for multiple dosing. The manufacturing methodology uses
|SOURCE MaxCyte, Inc.|
Copyright©2008 PR Newswire.
All rights reserved